Showing posts with label cancer vaccine. Show all posts
Showing posts with label cancer vaccine. Show all posts

June 28, 2013

$PVCT: Adam Feuerstein's Bifurcated Position on Cancer Immunotherapy, in general

From his June 28 Biotech Stock Mailbag. Bold emphasis is mine, as is bold underlined.
"Before I address a specific question about NewLink Genetics (NLNK), I want to lay down a bifurcated position on cancer immunotherapy in general. 
Position No. 1: Until I see convincing evidence of efficacy (successful phase III studies, FDA approvals) I am extremely skeptical of any company taking the "vaccine" approach to targeting cancer cells. I define a cancer vaccine as any therapy made up of tumor cells (autologous or patient specific), antigens or other immune-boosting agents designed to provoke the body's immune system to mount an attack on specific types of cancer cells. 
Who's in this cancer vaccine group? Dendreon (DNDN), of course. Provenge is approved, but it's a fluke and a commercial disappointment. The list of companies with failed cancer vaccines is much longer -- Cell Genesys, Genitope, Favrille, Oncothyreon (ONTY), Antigenics (AGEN), CancerVax, etc. 
Despite a lot of convincing evidence debunking the vaccine approach to cancer immunotherapy, tiny biotech companies push ahead -- NewLink, Galena Biopharma (GALE), Vical (VICL), Northwest Biotherapeutics (NWBO), ImmunoCellular Therapeutics (IMUC). I'm not a believer. I'll be happy to admit my error if/when one of these companies produces boffo clinical data. I just don't see that happening anytime soon. 
Position No. 2: The anti-PD1/PDL1 approach to cancer immunotherapy works. These therapies turn off a cloaking device used by cancer cells to hide from a patient's immune system. One way cancer cells grow is by donning molecular camouflage which tricks the immune system into thinking they're normal, healthy cells. The anti-PD1/PDL1 (and anti-CTLA4) drugs turn off cancer's cloaking device. Without the protective camo, the immune system attacks cancer cells as foreign and deadly. 
I just came back from the ASCO annual meeting where Bristol-Myers Squibb (BMY), Merck (MRK) and Roche (RHHBY) presented a lot of astounding clinical data on their respective anti-PD1/PDL-1 therapies. This is the positive direction in which the cancer immunotherapy field is headed. By comparison, cancer vaccine developers are driving into a dead end. 
Back to NewLink and its pancreatic cancer vaccine known as HyperAcute Pancreaa, or algenpantucel-L. Results from an interim analysis of an ongoing phase III study are expected soon. [The official guidance is mid-year.] 
This interim analysis is fundamentally meaningless. At best, it's another biotech catalyst for biotech traders to trade around. 
The most likely outcome of the interim analysis -- to be conducted after half of the expected number of deaths have occurred -- will be a determination to continue the study with final results ready next year. The bar to stop the study early for efficacy is really high -- estimated at a 45% improvement in overall survival for HyperAcute Pancreas relative to the control arm, according to NewLink. 
Notably, NewLink is not conducting a futility analysis concurrent with the early look at overall survival. A futility analysis determines whether an experimental drug is unlikely to confer a benefit relative to control. 
In other words, NewLink only wants to know if HyperAcute Pancreas works so well that victory can be declared early. The company doesn't want to know -- and will not learn -- if the vaccine has no chance of succeeding. 
Unfortunately, this half-blind approach to clinical trials is standard operating procedure for cancer vaccine developers."
Feuerstein's Position No. 1: "I define a cancer vaccine as any therapy made up of tumor cells (autologous or patient specific), antigens or other immune-boosting agents designed to provoke the body's immune system to mount an attack on specific types of cancer cells." ➟➟➟ Throwing around labels, like a cancer vaccine (or the Holy Grail of cancer, among other labels), very often poorly describes what you are trying to describe because you've used a poor label, you aren't using it "fully properly," or you don't fully understand the label you are using.

Let's start with Provectus' Society for Immunotherapy of Cancer (SITC) poster, where the company concluded the immuno-chemoablative response to PV-10 is tantamount to “in situ vaccination.”

PV-10 is not made up of tumor cells, antigens or other immune-boosting agents. It stimulates the immune system by virtue of the very large quantity of relevant and specific antigens the chemoablative properties of the drug facilitate and thus enable to be expressed. I suppose if we're being intellectually honest, PV-10 could be viewed as an immune-boosting agent, depending on what you mean or intend to mean by "boosting."

I don't think the company calls PV-10 a cancer vaccine, although Moffitt might, but I think they might consider it "vaccine-like" in how it stimulates the immune system.

From Wikipedia: "A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters."

The bold emphasis above is mine. PV-10, while not being the agent in the context of the verbiage above, does indeed stimulate the immune system. PV-10's chemoablative properties enable the creation of thousands of "agents" -- the very large quantity of relevant and specific antigens created after PV-10 is administered intralesionally into tumors -- that then are (i) recognized by the immune system as foreign, (ii) are remembered by the immune system, and thus (iii) easily recognized and destroyed by the immune system when they are later encountered.

Words matter. "Provoke" does not fully equal "stimulate."

Feuerstein's Position No. 2: "These therapies turn off a cloaking device used by cancer cells to hide from a patient's immune system." ➟➟➟ Anti-PD-1s/PDL-1s are the next wave of interesting immunotherapy agents, but that is neither the full sum nor the end of the story.

PV-10 triggers immune cell mediation, which is natural, after initial chemoablation occurs.  Again, words matter. "Turn off"/"turn on" are artificial, as in doing something artificial to the immune system (and thus, as Craig would say, to Mother Nature). PV-10 harnesses/employ/stimulates the immune system in a manner that, said colloquially, allows Mother Nature to do what she does best.

May 15, 2013

Moffitt's Phase 1 Feasibility Trial for $PVCT's PV-10 (follow-up)

A blog reader reminder me about the February article "Back to Phase 1: Understanding Systemic Effects of PV-10" in CancerWatch (Vol. 22 Feb. 2013) that discussed the background and motivation for Moffitt's Phase 1 study of the systemic antitumor effects of intralesional PV-10 treatment. It's worth re-reading the article again in the context of Moffitt purportedly completing the bulk of its feasibility study work.

“A further impetus toward teasing out the precise mechanism of how PV-10 can exert a systemic immune response in patients,” said Dr. Sarnaik in an interview, “is to allow us to rationally combine PV-10 treatment with some of the exciting emerging immunotherapies for metastatic melanoma.”

“We are really interested in harnessing immune cell infiltrate as a form of treatment,” he said, noting also that while creating cancer vaccines has been thought of traditionally as one of the Holy Grails of cancer research, cancer vaccines have turned out to be not strong enough to generate an adequate immune response.

Dr. Sarnaik said, only about half the time. “We generate large numbers of T-lymphocytes, but we 
don’t have control over their quality. We think one of the limitations is that the T cells you get out of the tumor just aren't good enough.” PV-10, however, does cause an immune response, suggesting that a combination treatment may improve the quality of the T-lymphocytes and have a greater impact on the disease. When Shari Pilon-Thomas, PhD, also a Moffitt researcher, demonstrated that T-lymphocytes recovered from mice treated with PV-10 do appear to be of a higher quality, as evidenced by stronger 
tumor reactivity, the stage was set for Dr. Sarnaik’s current 15-patient pilot study.

“This is a straightforward study that will give a yes or no answer,” Dr. Sarnaik said.

April 1, 2013

$PVCT: Understanding Why Cancer Vaccines Fail

This article from The Motley Fool is a nice read. The first part of the article revisits an MD Andersen discovery earlier this year that the incomplete Freund's adjuvant, or IFA, a mineral oil-based adjuvant, could be a problem.

The article also highlights other vaccine or vaccine-like treatments like Provenge (Dendreon), Yervoy (Bristol-Myers) and TheraCys (Sanofi), as well as Stimuvax (Oncothyreon) and Allovectin (Vical), ultimately concluding that "[T]he insights from the discovery at MD Anderson will help move cancer immunotherapies further along, but given the long list of failures, it's still a risky area to invest in."

In discussing the impact of these treatments on cancer (tumors), the author misses a critical point; namely, so-called cancer vaccines fail because they are not sufficiently effective directly on tumors in the first place. In other words, these treatments do not kill tumors well enough, while PV-10 does.

March 2, 2013

Late-night $PVCT...

“A further impetus toward teasing out the precise mechanism of how PV-10 can exert a systemic 
immune response in patients,” said Dr. Sarnaik in an interview, “is to allow us to rationally combine PV-10 treatment with some of the exciting emerging immunotherapies for metastatic melanoma.” The focus at Moffitt, Dr. Sarnaik continued, is on discerning the presence of immune cell infiltrate in untreated tumors after PV-10 injections into other lesions. “We are really interested in harnessing immune cell infiltrate as a form of treatment,” he said, noting also that while creating cancer vaccines has been thought of traditionally as one of the Holy Grails of cancer research, cancer vaccines have turned out to be not strong enough to generate an adequate immune response. CANCER WATCH, VOL. 22, FEBRUARY 2013

I kept coming back to this portion of the article for two reasons. First, was Sarnaik's quote rationally combining PV-10 with other exciting emerging immunotherapies. What, PV-10 isn't exciting? Second, was his quote about harnessing immune cell infiltrate as a form of treatment. A better cancer vaccine because of PV-10?

The crux of the matter is that PV-10, as a local agent, needs to show systemic potential for life science investors, Big Pharma and the FDA to view the drug as clinically relevant. This is the local agent "burden of proof." There must be systemic potential to be relevant for treating cancer after surgery, where cancer is viewed by definition as a systemic disease. PV-10 is an drug with tremendous local efficacy and before unseen systemic benefit (even more so than systemic agents).

But PV-10 still is a local agent.

The mindset of the industry -- medical oncologists and hematologist-oncologists, but not surgeons -- is that a local agent has to be combined with a systemic agent to be relevant.  The industry does not yet realize how much of an impact PV-10 will be just as a local agent. All it can currently understand is that PV-10 works, and harnesses the immune system in novel manner. It is obvious to industry PV-10 will get even better systemic results when combined with other agents, or, other agents will get better results when combined with PV-10.

I am getting hung up about trying to understanding PV-10's potential as a monotherapy, but that's not where the industry's mindset currently resides (i.e., as I wrote above, it's in combination for now). That should come, however, and probably quickly.

A tumor's core is an anaerobic necrotic area where more dangerous cancer cells reside, compared to the outer layers and exterior of the tumor where cancerous cells are less abnormal and virulent. Standard chemotherapy or radiation kills the "easy" cancerous targets on the periphery of the tumor. The "hard" targets in the anaerobic core are difficult for drugs and radiation to destroy. A very Darwinian natural selection process occurs. The more hardy and vicious variants in the core survive, feeding off of and expanding into the room provided by the destruction of the easier-to-kill cancer cells at the periphery. Tumors re-occur and the next generation of them is drug- and radiation-resistant, having selected for the more virulent population. If you miss with the first round, everything is made worse for the patient.

The historic and current work on cancer vaccines faces the challenge of not being strong enough to generate an adequate immune response. Like with failed chemotherapy or radiation, where the treatment miss makes everything worse for the patient, vaccines are inducing tolerance by repeated exposure to antigens, convincing the immune not to react to tumor-associated antigens.

Recall Craig et al.'s conclusion at SITC:


PV-10 in situ vaccination. Let the the antigen presenting cells (APCs) pick the antigen, rather than the other way around (as others are doing) and kill the tumor in situ. Let the APCs do their job and present antigens to T cells.

Moffitt, however, through their focus on adoptive T cell immunotherapy, believes PV-10 induces better T cells. T cell activation to very specific tumor targets. The ability to transfer immunity. Notice Moffitt's AACR abstract about PV-10 inducing a systemic anti-tumor immune response in murine models of melanoma and, now, breast cancer. More cancer indications validated by Moffitt on the way?

Moffitt, it seems to me, thinks PV-10 is the pathway to a more potent (i.e., generates a much stronger immune response), more effective (i.e., it heals, it cures), more broad (i.e., multi-indication) cancer vaccine.

I admit this post is a work in progress. The much greater point is understanding what PV-10 does to the immune system. PV-10: The Holy Grail? The cure for cancer? Perhaps...

December 21, 2012

Cancer Vaccines

"Some researchers believe that cancer cells routinely arise and are destroyed by the healthy immune system;[2] cancer forms when the immune system fails to destroy them.[3]" Source article here from Wikipedia (from where preceding quote was taken).

Footnote [2]: Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. (2001-04-26). "IFNbig gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity." Nature 410 (6832): 1107–1111.
Abstract: After a century of controversy, the notion that the immune system regulates cancer development is experiencing a new resurgence. An overwhelming amount of data from animal models—together with compelling data from human patients—indicate that a functional cancer immunosurveillance process indeed exists that acts as an extrinsic tumor suppressor. However, it has also become clear that the immune system can facilitate tumor progression, at least in part, by sculpting the immunogenic phenotype of tumors as they develop. The recognition that immunity plays a dual role in the complex interactions between tumors and the host prompted a refinement of the cancer immunosurveillance hypothesis into one termed “cancer immunoediting.” In this review, we summarize the history of the cancer immunosurveillance controversy and discuss its resolution and evolution into the three Es of cancer immunoediting—elimination, equilibrium, and escape.
Footnote [3]: Dunn GP, Old LJ, Schreiber RD. (2004). "The three Es of cancer immunoediting." Annual Rev Immunology 22 (1): 329–360.
Abstract: Lymphocytes were originally thought to form the basis of a 'cancer immunosurveillance' process that protects immunocompetent hosts against primary tumour development, but this idea was largely abandoned when no differences in primary tumour development were found between athymic nude mice and syngeneic wild-type mice. However, subsequent observations that nude mice do not completely lack functional T cells and that two components of the immune system—IFNbig gamma and perforin—help to prevent tumour formation in mice have led to renewed interest in a tumour-suppressor role for the immune response. Here we show that lymphocytes and IFNbig gamma collaborate to protect against development of carcinogen-induced sarcomas and spontaneous epithelial carcinomas and also to select for tumour cells with reduced immunogenicity. The immune response thus functions as an effective extrinsic tumour-suppressor system. However, this process also leads to the immunoselection of tumour cells that are more capable of surviving in an immunocompetent host, which explains the apparent paradox of tumour formation in immunologically intact individuals.

#NYT: Is the Cure for Cancer Inside You?

Steinman knew he wouldn’t live to see that field reach its full potential. It has been almost 40 years since he discovered the dendritic cell, and doctors have only now begun to make immunotherapies that work. By all accounts, that sluggish pace was deeply frustrating to Steinman, even before he got sick. “His mind went so fast, and he always wanted everything done yesterday,” Schlesinger says. Years ago, the two of them were on their way to their lab, and Steinman was in a foul mood because a trial they hoped to run was taking longer than expected. After some back and forth about the details, he stopped to consider what he had accomplished in his long career. “He said to me, ‘You know, all this time has gone by, and we haven’t cured cancer or found a vaccine for H.I.V.’ ” And then he paused, and told her, “We’ve got to get to work.”
Full article by Daniel Engber here.

$PVCT: What Could An Autopsy of Failed Drug $ONTY Tell Us About $PVCT

I found Martin Shkreli's article on TheStreet.com about Oncothyreon's Stimuvax failure a few days ago interesting. Shkreli wrote an earlier article too on the same topic in July 2011. It's the second article and the section on Mechanism of Action that I want to focus on (bold is my emphasis).
Stimuvax is often referred to as a MUC1 “cancer vaccine”. The problem with this terminology is Stimuvax is not a vaccine in any way, shape or form.­­ Vaccines typically stimulate an immune response against an introduced antigen. This allows the immune system to fight off this antigen in the future. 
MUC1 is widely expressed in humans. Stimuvax is liposomal MUC1, so Stimuvax can’t be a MUC1 vaccine because the immune system won’t know that MUC1 is an antigen to fight off. 
Without some leukopheresis/immune-training process, a-la Dendreon or a specialized adjuvant, it is difficult to generate a vaccine to an endogenously found peptide. A MUC1 antibody or small molecule antagonist would make a lot more sense. Indeed, several companies are attempting to improve the immune response for prospective MUC1 vaccines as well as attempting targeted payload strategies for MUC1. MUC1 is certainly a good marker for cancer, but it still isn’t useful. MUC1 tests are no longer used. MUC16, which you may know better as CEA125, is widely used to determine ovarian cancer staging and status. Antibodies, armed antibodies and vaccines to CEA125 went nowhere.
According to the NIH’s protein database, mucin 1 (MUC1) is a 1255 amino acid protein. Stimuvax is the common repeat found in mucin 1. I wonder if the inventors assumed this will serve as an antigen to the immune system and T cells will destroy any cell with mucin 1 expression. It doesn’t take a cell biologist to appreciate this is not a good idea given the widespread expression of MUC1. 
Furthermore, without legitimate immune response data and with no side effects, my supposition that Stimuvax is inert is likely correct. The tandem repeat found in Stimuvax is no different from native MUC1. While the glycosylation patterns may be different, it’s hard to see MUC1 inducing a potent immune response. Indeed, the failure of the similar MUC16 to generate a viable anticancer candidate bodes poorly for MUC1 and Stimuvax.
Getting back to the question of whether Stimuvax is an effective vaccine, we noticed that only 21% of Stimuvax patients in the Phase IIB study had an immune response to Stimuvax. Because the only way Stimuvax could have any anti-cancer effect would be through immune recognition of the MUC1 tandem repeat, and a subsequent immune response strong enough to destroy MUC1 expressing cells (a long shot), a 21% immune response (forget evidence of a CR/PR) is not promising. 
Most good vaccines have to have 100% immune responses or close to it. The immune response data is uncontrolled and hazy at best. For a drug billed as a vaccine, Stimuvax doesn’t do a great job of proving it is a vaccine. Even in a small n=22 trial that tested a new formulation of Stimuvax, immune response results were not disclosed.
Oncothyreon tried the Dendreon approach of cherry picking antigens to generate immune responses. Immunotherapuetic advancements need to harness much more comprehensive immune-mediated response than limiting selection criteria.

I think Moffitt will have a lot more to say about vaccine-like PV-10.